• Vaccine Name: ChAd63 MVA PvDBP
• Target Pathogen: Plasmodium spp.
• Target Disease: Malaria
• Type: Recombinant vector vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: PvDBPII: region II of P. vivax Duffy-binding protein (Hou et al., 2022)
• PvDBPII gene engineering:
  • Type: Recombinant protein preparation
  • Description: Region II of PvDBP, a 327-amino acid domain. (Hou et al., 2022)
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: Prime-boosting vaccine that use different vectors: ChAd63 PvDBP is the prime vaccination and MVA PvDBP is the booster. (Hou et al., 2022)

Human Response

• Vaccination Protocol: Non-randomized, Phase IIa study.
  Group 1 participants received 5 x 10^10 vp ChAd63 PvDBP and 2 x 10^8 pfu MVA PvDBP 8 weeks later, followed by CHMI 2–4 weeks later. Group 2 received one dose of 5 x 10^10 vp ChAd63 PvDBP, and 12-18 months later received a second dose of 5 x 10^10 vp ChAd63 PvDBP and 8 weeks later 2 x 10^8 pfu MVA PvDBP. Group 3 participants received 5 x 10^10 vp ChAd63 PvDBP and 2 x 10^8 pfu MVA PvDBP 8 weeks later, followed by CHMI 2–4 weeks later. Group 3 participants received the first dose 2 years later than participants in group 1 and had CHMI at the same time with participants in Group 2. (Hou et al., 2022)
• Challenge Protocol: CHMI 2–4 weeks after booster vaccination (Hou et al., 2022)
• Efficacy: All volunteers developed parasitemia. There was no significant difference in PMR or LCP compared to the controls. (Hou et al., 2022)